Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404)
| Autor: | M. B. Jameson, M. J. McKeage |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry non-small cell lung cancer (NSCLC) Histology Pharmacology Stage iiib medicine.disease Carboplatin law.invention chemistry.chemical_compound chemistry Paclitaxel Randomized controlled trial law Non squamous Internal medicine medicine business Median survival |
| Zdroj: | Journal of Clinical Oncology. 26:8072-8072 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.8072 |
| Popis: | 8072 Background: DMXAA (ASA404) is a tumor vascular disrupting agent recently evaluated in phase II trials in NSCLC. A randomized trial compared DMXAA 1,200 mg/m2 plus carboplatin and paclitaxel (CP) with CP alone (median survival 14.0 vs 8.8 months). A single-arm study evaluated DMXAA 1,800 mg/m2 plus CP (median survival 14.9 months). Both trials included squamous and non-squamous patients. We examined whether the safety or efficacy of DMXAA varied with histology. Methods: Patients had chemotherapy-naive stage IIIb/IV NSCLC. Phase II data were pooled by histology and treatment, with aggregation of the two DMXAA doses. We compared efficacy and safety between squamous and non-squamous patients receiving the same treatment. Then for each histology we compared patients receiving and not receiving DMXAA. Results: Numbers of patients evaluable for safety (efficacy) were: in the CP arm of the randomized study, 11 (11) squamous and 25 (25) non-squamous; in the CP + DMXAA 1,200 mg/m2 arm of the randomized study, ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|